Peijia Medical Secures Tens of Millions in USD Series A Funding Led by Matrix Partners China to Fill Domestic Gap in Transcatheter Heart Valve Market

(Some information in this article is sourced from the official WeChat account of the Suzhou Industrial Park SME Service Center.)

Peijia Medical is a high-tech enterprise dedicated to the research and development, production, and sales of advanced medical devices for the treatment of structural heart disease, with a registered capital of RMB 30 million. On March 29, 2016, Peijia Medical announced that it had secured tens of millions of US dollars in Series A financing, led by Matrix Partners China.The Heart Valve Sector Boasts a Promising Market Outlook, and Peijia Medical Has Achieved Precise Strategic Positioning at Its InceptionPeijia Medical has positioned its entrepreneurial focus on the interventional heart valve sector, a market segment that remains largely untapped in China. Currently, the company has established an R&D laboratory for transcatheter aortic valve implantation (TAVI) in Shanghai Zhangjiang Pharma Valley. This facility is dedicated to the research, development, and production of TAVI products, as well as the R&D and experimental work on cutting-edge technologies such as mitral valve interventions. Meanwhile, Peijia Medical has invested in building a manufacturing plant in Suzhou Industrial Park.

The Company holds four invention patents in the field of “artificial heart valves.” Its product portfolio includes detachable coils for the treatment of hemangiomas, self-expanding mesh stents for intracranial arteries, and delivery sheaths for intracranial self-expanding stent delivery systems.

Peijia Medical ResearchCompany’s Technology Significantly Improves Survival Rates for Heart Disease Patients; Matrix Partners China Bullish on Peijia Medical Team’s CapabilitiesTranscatheter aortic valve replacement (TAVR), a revolutionary new therapeutic approach that has emerged in recent years, is hailed as the most innovative invention in the field of interventional cardiology. This technique employs a procedural approach nearly identical to that of coronary stenting, offering advantages such as minimal invasiveness, reduced pain, shorter hospital stays, and faster recovery. Transcatheter intervention has significantly improved the survival rates of patients with heart disease.

According to authoritative estimates, the volume of percutaneous interventional heart valve procedures is poised for explosive growth over the next five years, while the adoption of transcatheter aortic valve implantation (TAVI) will rise exponentially from its current baseline. The aortic valve TAVI product developed by Peijia Medical will bring about significant innovation to the treatment of valvular heart disease in China.。Regarding the lead investment in Peijia Medical, Yu Zhiyun, Investment Director at Matrix Partners China (MPCi), stated that they were attracted by the Peijia founding team’s impressive track record in the field of domestic cardiac interventional devices, as well as the company’s confidence, determination, and R&D capabilities to fill the market gap in the domestic interventional heart valve sector. Yu Zhiyun said, “We look forward to Peijia Medical making greater contributions to improving the well-being of patients with structural heart disease in China.”

About Matrix Partners ChinaMatrix Partners China was established in 2008 and currently manages four US dollar funds and four RMB funds, with a total value of RMB 15 billion. Focusing on early-stage investments, Matrix Partners China has invested in over 300 companies, primarily in the internet and healthcare sectors. Its portfolio includes notable companies such as Momo, Cheetah Mobile, Didi Kuaidi, Pocket Shopping (Weidian), Ele.me, iKang Guobin, and Edan Instruments. The investment team at Matrix Partners comprises more than 40 professionals with extensive industry experience and networks. By leveraging specialized sub-teams to accumulate sector-specific knowledge, the firm systematically identifies high-quality companies. Additionally, it provides robust post-investment support to entrepreneurs through services covering government relations (GR), public relations (PR), recruitment, legal affairs, healthcare, finance, and capital markets.